The Lymphoma Channel is supported with funding from AstraZeneca (Diamond), BMS (Gold), Johnson & Johnson (Gold), Takeda (Silver) and Galapagos (Bronze).
The Multiple Myeloma Channel is supported with funding from BMS (Gold) and Legend Biotech (Bronze).
VJHemOnc is an independent medical education platform. Supporters, including channel supporters, have no influence over the production of content. The levels of sponsorship listed are reflective of the amount of funding given to support the channel.
EHA 2021 | Where is the researching moving in CAR-T?
Peihua Lu, MD, Lu Daopei Hospital, Langfang, China and Lu Daopei Institute of Hematology, Beijing, China, discusses future research in the field of chimeric antigen receptor T-cell (CAR-T) therapies, highlighting recent approvals in B-cell malignancies and myeloma, and commenting on the potential role of CAR-T therapies in T-cell and myeloid malignancies. Dr Lu also highlights the need to decrease toxicities, decrease the manufacturing costs and increase the duration of responses. This interview took place at the virtual European Hematology Association (EHA) Congress 2021.
